Gentamicin Prescribing in Adults

1. Clinical Overview

Gentamicin is a bactericidal aminoglycoside antibiotic with potent activity against aerobic Gram-negative bacteria, including Pseudomonas aeruginosa. [1] It is characterized by:

• Narrow therapeutic index: Small margin between therapeutic and toxic concentrations [2]
• Concentration-dependent killing: Efficacy correlates with peak concentration (Cmax) relative to minimum inhibitory concentration (MIC) [3]
• Post-antibiotic effect (PAE): Bacterial suppression persists after drug levels fall below MIC, permitting extended-interval dosing [4]
• Toxicity related to trough accumulation: Nephrotoxicity and ototoxicity correlate with sustained trough levels [5]

The fundamental principle: Maximize peak concentration for efficacy while minimizing trough accumulation to reduce toxicity. This pharmacodynamic profile forms the rationale for once-daily (extended-interval) dosing. [6]

---

2. Pharmacology

2.1 Mechanism of Action

Gentamicin irreversibly binds to the 30S ribosomal subunit, causing:

1. Misreading of mRNA codons → aberrant protein synthesis [7]
2. Disruption of ribosomal proofreading
3. Membrane dysfunction from abnormal proteins
4. Cell death (bactericidal)

The bactericidal effect is concentration-dependent: higher peak concentrations achieve more rapid and complete bacterial killing. [3]

2.2 Antimicrobial Spectrum

Primary Activity (Excellent):

• Gram-negative aerobes: Escherichia coli, Klebsiella spp., Proteus spp., Enterobacter spp., Serratia spp.
• Pseudomonas aeruginosa [1]
• Synergistic activity with beta-lactams against enterococci and staphylococci (endocarditis) [8]

Limited/No Activity:

• Anaerobes (require oxygen-dependent uptake)
• Streptococci (intrinsic low-level resistance)
• Intracellular organisms
• Fungi

2.3 Pharmacokinetics

Key Implications:

• Hydrophilic: Does not penetrate adipose tissue → use ideal or adjusted body weight in obese patients [10]
• Renal elimination: Accumulates in renal impairment; contraindicated in severe AKI [14]
• Minimal CSF penetration: Not suitable for CNS infections [15]

2.4 Concentration-Dependent Killing and Post-Antibiotic Effect

Two critical pharmacodynamic properties distinguish aminoglycosides:

1. Concentration-Dependent Killing: Increasing peak concentrations above MIC produce progressively greater bactericidal activity. Optimal efficacy requires peak:MIC ratio ≥8-10. [3,16]

2. Post-Antibiotic Effect (PAE): Bacterial growth suppression persists for 2-8 hours after drug levels fall below MIC, particularly against Gram-negative organisms. [4] This permits:

   • Extended dosing intervals
   • Reduced total daily exposure
   • Lower toxicity risk

These properties form the pharmacological foundation for once-daily dosing. [6]

---

3. Clinical Indications

3.1 Primary Indications

3.2 Microbiological Considerations

Gentamicin is indicated when suspected or confirmed susceptible Gram-negative infection, particularly:

• Severe sepsis requiring anti-pseudomonal cover [17]
• Multidrug-resistant Gram-negatives (check local resistance patterns) [22]
• Synergistic therapy for enterococcal/streptococcal endocarditis [8]

Always review therapy at 48-72 hours: De-escalate based on culture results and clinical response. Prolonged aminoglycoside use (> 5-7 days) significantly increases toxicity risk. [23]

---

4. Toxicity and Contraindications

4.1 Nephrotoxicity

Incidence: 10-25% of patients (varies with definition, duration, concomitant nephrotoxins) [24,25]

Mechanism:

• Proximal tubular uptake via megalin-mediated endocytosis [26]
• Accumulation in renal cortex (concentrations 50-100× plasma) [27]
• Mitochondrial dysfunction and oxidative stress
• Acute tubular necrosis (ATN)

Clinical Features:

• Non-oliguric renal impairment
• Rising serum creatinine (typically day 5-7) [24]
• Electrolyte wasting (hypomagnesemia, hypokalemia)
• Tubular proteinuria
• Usually reversible if drug stopped promptly [28]

Risk Factors: [25,29]

• Duration > 5-7 days
• Elevated trough levels
• Pre-existing renal impairment
• Volume depletion
• Concomitant nephrotoxins (NSAIDs, vancomycin, contrast, amphotericin B, loop diuretics)
• Advanced age
• Liver disease

Monitoring:

• Daily serum creatinine
• Electrolytes (Mg²⁺, K⁺)
• Urinalysis
• Drug levels (trough concentrations)

4.2 Ototoxicity

Incidence: Vestibular 4-6%; auditory 3-14% (often underdiagnosed) [30,31]

Mechanism:

• Uptake by cochlear and vestibular hair cells [32]
• Mitochondrial dysfunction and generation of reactive oxygen species
• Irreversible damage to type I hair cells
• Genetic susceptibility: Mitochondrial 12S rRNA mutations (A1555G) confer markedly increased risk [33]

Clinical Features:

Risk Factors: [30,31]

• Prolonged therapy (> 14 days highest risk)
• Elevated trough concentrations
• Concomitant ototoxins (loop diuretics, cisplatin)
• Pre-existing hearing impairment
• Renal impairment (accumulation)
• Genetic predisposition (mitochondrial mutations)
• Advanced age

Monitoring:

• Baseline audiometry (if prolonged therapy anticipated)
• Serial audiometry weekly if therapy > 7 days
• Daily assessment: tinnitus, hearing loss, vertigo
• STOP IMMEDIATELY if symptoms develop [31]

4.3 Neuromuscular Blockade

Mechanism: Inhibits presynaptic acetylcholine release and blocks postsynaptic receptors. [34]

Clinical Significance:

• ABSOLUTE CONTRAINDICATION in myasthenia gravis (can precipitate myasthenic crisis/respiratory failure) [35]
• Potentiates non-depolarizing neuromuscular blockers (perioperative caution)
• Rare in standard dosing without neuromuscular disease

Treatment: IV calcium gluconate or neostigmine if blockade occurs. [34]

4.4 Contraindications

4.5 Drug Interactions

---

5. Dosing Regimens: Once-Daily vs. Multiple-Daily

5.1 Once-Daily (Extended-Interval) Dosing

The STANDARD regimen for most indications. [6,39]

Rationale:

• Exploits concentration-dependent killing: High peak achieves optimal bactericidal activity [3]
• Exploits post-antibiotic effect: Extended interval allows complete washout [4]
• Reduces toxicity: Lower trough concentrations minimize renal cortical accumulation [40]
• Improved convenience and cost-effectiveness [41]

Evidence: Multiple meta-analyses demonstrate once-daily dosing is at least as effective as multiple-daily dosing, with reduced nephrotoxicity and similar or reduced ototoxicity. [6,39,42]

Standard Dose: 5-7 mg/kg IV once daily [43,44]

Dosing Interval: Determined by renal function and therapeutic drug monitoring (see Section 5.4).

5.2 Multiple-Daily Dosing

Reserved for SPECIFIC indications where sustained gentamicin levels required:

1. Endocarditis (synergistic therapy): [8]

   • 1 mg/kg every 8-12 hours (NOT 5-7 mg/kg)
   • Target: Peak 3-5 mg/L, Trough less than 1 mg/L
   • Synergy with beta-lactams depends on sustained levels, not high peaks

2. Pregnancy (if absolutely necessary): [36]

   • Lower peaks may reduce fetal exposure
   • Specialist consultation mandatory

Evidence for endocarditis: Historical regimens used multiple-daily dosing; insufficient evidence to support once-daily dosing for synergy. [8] Current guidelines recommend conventional dosing.

5.3 Weight-Based Dosing Considerations

Gentamicin distributes in extracellular fluid, not adipose tissue. [10] Using actual body weight in obese patients results in overdosing and toxicity.

Dosing Weight Calculation:

Ideal Body Weight (IBW):

• Males: 50 kg + 2.3 kg per inch over 5 feet
• Females: 45.5 kg + 2.3 kg per inch over 5 feet

Example:

• Male, 180 cm (5'11"), 120 kg
• IBW = 50 + (11 × 2.3) = 75.3 kg
• ABW = 75.3 + 0.4 × (120 - 75.3) = 75.3 + 17.9 = 93.2 kg
• Dose = 7 mg/kg × 93.2 = 652 mg (NOT 840 mg if actual weight used)

5.4 Renal Dose Adjustment

Gentamicin clearance directly correlates with creatinine clearance. [14]

Once-Daily Dosing in Renal Impairment:

CRITICAL: In acute kidney injury or fluctuating renal function, nomograms are unreliable. Therapeutic drug monitoring is MANDATORY. [50]

---

6. Therapeutic Drug Monitoring (TDM)

6.1 Rationale for TDM

Gentamicin has:

• Narrow therapeutic index [2]
• Large inter-patient pharmacokinetic variability [51]
• Serious dose-related toxicity [24,30]

TDM is ESSENTIAL to:

• Ensure therapeutic concentrations (efficacy)
• Minimize toxicity (safety)
• Guide dosing interval adjustments

6.2 Target Concentrations

Once-Daily Dosing:

Multiple-Daily Dosing (Endocarditis):

6.3 Hartford (Once-Daily) Nomogram

The Hartford nomogram uses a single level drawn 6-14 hours post-dose to determine the dosing interval. [53]

Procedure:

1. Administer standard dose (5-7 mg/kg) IV over 30-60 minutes
2. Draw blood sample 6-14 hours after start of infusion (record exact time)
3. Plot concentration vs. time on nomogram
4. Determine interval based on zone:

Gentamicin Hartford Nomogram

Concentration (mg/L)
       |
    12 |---------------------------- Zone A (Q24h)
       |
     8 |
       |---------------------------- Zone B (Q36h)
     6 |
       |
     4 |---------------------------- Zone C (Q48h)
       |
     2 |
       |---------------------------- Zone D (>Q48h or seek advice)
     1 |
       |
     0 |_____|_____|_____|_____|_____|
           6     8    10    12    14
              Hours post-dose

Zone Interpretation:

• Zone A (level at 8h > 6 mg/L): Normal clearance → Q24h dosing
• Zone B (level at 8h 4-6 mg/L): Mild impairment → Q36h dosing
• Zone C (level at 8h 2-4 mg/L): Moderate impairment → Q48h dosing
• Zone D (level at 8h less than 2 mg/L): Severe impairment → >Q48h or stop; seek specialist advice

Advantages: [53,54]

• Simpler than traditional peak/trough
• Single blood draw (cost-effective, convenient)
• Validated in diverse populations
• Reduces supratherapeutic troughs

Limitations:

• Assumes first-order kinetics (not valid in severe renal impairment)
• Less accurate if sample timing incorrect
• Not validated for endocarditis (multiple-daily) dosing

6.4 Traditional Peak and Trough Monitoring

Used for multiple-daily dosing (endocarditis) or when Hartford nomogram not applicable.

Sampling:

• Peak: 30-60 minutes after end of IV infusion (reflects distribution phase completion) [55]
• Trough: Immediately before next dose (less than 30 min pre-dose)

Frequency:

• Initial levels: After 3rd-4th dose (steady state)
• Subsequently: 2-3 times weekly, or more frequently if:
  • Renal function changing
  • Clinical deterioration
  • Prolonged therapy (> 7 days)

6.5 Dose Adjustment Based on Levels

If Trough > 1 mg/L (TOXIC):

1. WITHHOLD dose
2. Repeat trough in 12-24 hours
3. Resume when less than 1 mg/L with extended interval or reduced dose
4. Investigate: renal function, drug interactions, hydration status
5. Consider alternative antibiotic if levels remain elevated

If Peak Subtherapeutic (less than 15-20 mg/L on once-daily):

1. Increase dose (maintain same interval)
2. Recheck level after 1-2 doses

If Inadequate Response Despite Therapeutic Levels:

1. Review microbiology (resistance? MIC?)
2. Review source control (abscess drainage? device removal?)
3. Consider alternative/additional antibiotics

---

7. Administration

7.1 Route and Preparation

• Route: Intravenous (IV) preferred; intramuscular (IM) acceptable if IV access unavailable [9]
• Preparation: Dilute in 50-100 mL normal saline or 5% dextrose
• Infusion time: 30-60 minutes [56]
  • Too rapid → higher peak concentrations (may increase ototoxicity risk)
  • Too slow → lower peak concentrations (reduced efficacy)

7.2 Compatibility

Compatible:

• Normal saline
• 5% dextrose
• Lactated Ringer's (short-term)

INCOMPATIBLE (DO NOT MIX in same IV line): [38]

• Penicillins (especially ticarcillin, piperacillin) - in vitro inactivation
• Heparin
• Furosemide
• Amphotericin B

Administer via separate IV line or flush line between drugs.

---

8. Monitoring Protocol

8.1 Baseline Assessment (Before First Dose)

8.2 During Therapy

8.3 Duration of Therapy

General Principle: Use gentamicin for the SHORTEST duration possible. [23]

CRITICAL: Prolonged aminoglycoside therapy (> 7 days) significantly increases toxicity risk without proven additional benefit in most infections. [23,58]

---

9. Special Populations

9.1 Elderly

Considerations:

• Reduced renal function (often underestimated by serum creatinine due to reduced muscle mass) [59]
• Calculate CrCl using Cockcroft-Gault formula
• Increased risk of ototoxicity and nephrotoxicity [30,59]
• Lower doses or extended intervals often required
• More frequent TDM

9.2 Obesity

• Use Adjusted Body Weight (see Section 5.3) [48]
• Standard mg/kg dosing with ABW is safe and effective [60]
• Volume of distribution may still be increased → monitor levels closely

9.3 Critical Illness

Augmented renal clearance (ARC): Critically ill patients with preserved renal function may have elevated CrCl (> 130 mL/min). [61]

Implications:

• Higher doses may be required (7 mg/kg)
• More frequent dosing (q18-24h even with normal creatinine)
• Mandatory TDM after first dose

Increased Vd: Sepsis, capillary leak, fluid resuscitation increase extracellular fluid volume. [45]

• May require higher initial doses
• Check levels early (after 1st dose)

9.4 Pregnancy

FDA Category D: Evidence of fetal risk (ototoxicity). [36]

Recommendations:

• Avoid if possible
• If essential (severe Gram-negative sepsis):
  • Use lowest effective dose
  • Shortest duration
  • Consider multiple-daily dosing (lower peaks may reduce fetal exposure)
  • Specialist consultation
  • Informed consent regarding fetal risks

9.5 Breastfeeding

• Minimal excretion in breast milk
• Poor oral absorption by infant
• Generally considered compatible, but monitor infant for diarrhea [62]

9.6 Hemodialysis

• Gentamicin is dialyzable (removed by hemodialysis) [49]
• Post-dialysis dosing: Administer full dose (5-7 mg/kg based on dry weight) after dialysis session
• Redose after each dialysis
• Mandatory TDM: Pre-dialysis trough should be less than 1 mg/L

9.7 Continuous Renal Replacement Therapy (CRRT)

• Unpredictable clearance (depends on modality, flow rates, membrane) [63]
• Loading dose: 5-7 mg/kg
• Maintenance: Variable (typically 2.5-3 mg/kg q24-48h)
• Essential TDM: Individualize based on levels

---

10. Clinical Scenarios and Decision-Making

10.1 Scenario 1: Severe Sepsis with Unknown Source

Presentation: 65-year-old male, febrile (39.2°C), hypotensive (BP 85/50), lactate 4.2 mmol/L, WCC 18 × 10⁹/L. Creatinine 90 μmol/L (baseline 85). Weight 80 kg.

Antibiotic Plan:

• Broad-spectrum beta-lactam (e.g., piperacillin-tazobactam 4.5 g IV q6h)
• Gentamicin 7 mg/kg = 560 mg IV once daily (severe sepsis dose)

Monitoring:

• Hartford level at 8 hours post-dose → adjust interval
• Daily creatinine
• Review at 48 hours: cultures, clinical response → de-escalate gentamicin if possible

10.2 Scenario 2: Obese Patient with Pyelonephritis

Presentation: 45-year-old female, flank pain, fever. Weight 110 kg, height 165 cm (5'5"). Creatinine 75 μmol/L.

Dose Calculation:

• IBW (female) = 45.5 + (5 × 2.3) = 57 kg
• ABW = 57 + 0.4 × (110 - 57) = 57 + 21.2 = 78.2 kg
• Dose = 5 mg/kg × 78.2 = 391 mg (round to 400 mg)

Error to Avoid: Dosing based on 110 kg (550 mg) would cause toxicity.

10.3 Scenario 3: Endocarditis

Presentation: 50-year-old with native valve endocarditis due to Enterococcus faecalis. Weight 75 kg, normal renal function.

Regimen:

• Amoxicillin 2 g IV q4h
• Gentamicin 1 mg/kg (75 mg) IV q8h (NOT 5-7 mg/kg)

Monitoring:

• Peak (1h post-dose): Target 3-5 mg/L
• Trough (pre-dose): Target less than 1 mg/L
• Duration: 2 weeks (of total 4-6 week course)

10.4 Scenario 4: Rising Creatinine on Day 5

Presentation: Patient receiving gentamicin 480 mg IV q24h. Day 5: creatinine 150 μmol/L (baseline 80 μmol/L). Trough level 1.8 mg/L.

Action:

1. WITHHOLD gentamicin immediately
2. Ensure adequate hydration
3. Review concomitant nephrotoxins (stop NSAIDs, minimize contrast)
4. Repeat trough in 24 hours
5. Reassess antibiotic choice: Can therapy be de-escalated/changed?
6. If gentamicin essential: Resume when trough less than 1 mg/L with extended interval (q48h or greater)

10.5 Scenario 5: Patient Reports Tinnitus

Presentation: Day 4 of gentamicin. Patient reports new-onset ringing in ears.

Action:

1. STOP gentamicin IMMEDIATELY (ototoxicity may be irreversible) [31]
2. Audiology referral (urgent)
3. Document clearly in notes
4. Switch to alternative antibiotic
5. Never rechallenge with gentamicin

---

11. Antimicrobial Stewardship

11.1 When to START Gentamicin

Appropriate:

• Severe sepsis/septic shock requiring empirical Gram-negative cover (particularly anti-pseudomonal) [17]
• Culture-directed therapy for susceptible Gram-negative organisms
• Synergistic therapy in endocarditis [8]

Inappropriate:

• Mild/moderate infections treatable with oral agents
• Uncomplicated UTI (use oral antibiotics)
• Empirical therapy without re-evaluation at 48-72 hours
• "Just in case" continuation beyond culture results

11.2 When to STOP Gentamicin

Mandatory review at 48-72 hours: [23]

Default duration for empirical gentamicin: Maximum 48-72 hours unless specific indication for continuation. [17,23]

11.3 Alternatives to Gentamicin

When gentamicin is contraindicated or unsuitable:

---

12. Key Examination Pearls

12.1 High-Yield Facts

1. Concentration-dependent killing: Efficacy depends on peak:MIC ratio (target ≥8-10). [3]

2. Post-antibiotic effect: Allows once-daily dosing by permitting extended drug-free intervals. [4]

3. Toxicity is trough-dependent: Nephrotoxicity and ototoxicity correlate with sustained trough levels (target less than 1 mg/L). [52]

4. Once-daily dosing is superior: Equal efficacy, reduced nephrotoxicity vs. multiple-daily dosing. [6,39]

5. Use ideal/adjusted body weight: Gentamicin does not distribute into adipose tissue. Dosing obese patients on actual weight causes toxicity. [10,48]

6. Myasthenia gravis is an ABSOLUTE contraindication: Neuromuscular blockade can cause respiratory failure. [35]

7. Ototoxicity may be irreversible: Stop immediately if tinnitus, vertigo, or hearing loss develops. [31]

8. Endocarditis dosing is different: 1 mg/kg q8-12h (NOT 5-7 mg/kg once daily). [8]

9. Mandatory therapeutic drug monitoring: Narrow therapeutic index requires level monitoring to ensure efficacy and avoid toxicity. [2,52]

10. Short duration is key: Prolonged use (> 7 days) dramatically increases toxicity without proven benefit in most infections. [23,58]

12.2 Common OSCE/Viva Questions

Q: Why is gentamicin given once daily rather than multiple times per day?

A: Gentamicin exhibits concentration-dependent killing (higher peaks achieve better bacterial kill) and a post-antibiotic effect (bacteria remain suppressed after levels drop below MIC). Once-daily dosing achieves high peaks for efficacy while allowing complete washout to low troughs, minimizing toxicity. Meta-analyses show once-daily dosing is equally effective with reduced nephrotoxicity. [3,4,6,39]

Q: How do you dose gentamicin in an obese patient?

A: Gentamicin is hydrophilic and distributes in extracellular fluid, not adipose tissue. In obese patients (> 20% above IBW), use Adjusted Body Weight = IBW + 0.4 × (Actual - IBW) to avoid overdosing and toxicity. [10,48]

Q: What is the Hartford nomogram?

A: The Hartford nomogram is a simplified once-daily gentamicin monitoring method. A single level is drawn 6-14 hours post-dose and plotted on a nomogram to determine the dosing interval (q24h, q36h, q48h, or longer) based on the patient's renal clearance. [53]

Q: A patient on gentamicin reports tinnitus. What do you do?

A: STOP gentamicin immediately. Ototoxicity may be irreversible. Arrange urgent audiology assessment. Switch to an alternative antibiotic. Document clearly and never rechallenge with gentamicin. [31]

Q: Why is gentamicin contraindicated in myasthenia gravis?

A: Aminoglycosides inhibit presynaptic acetylcholine release and block postsynaptic nicotinic receptors, exacerbating neuromuscular blockade. This can precipitate myasthenic crisis with respiratory failure. [34,35]

Q: What are the target peak and trough levels for once-daily gentamicin?

A: Peak (Cmax): > 20 mg/L (severe sepsis) or > 15 mg/L (other indications). Trough (pre-dose): less than 1 mg/L to minimize toxicity. [3,45,52]

Q: How does gentamicin dosing differ in endocarditis?

A: Endocarditis requires synergistic (not bactericidal) levels. Use 1 mg/kg q8-12h (multiple-daily dosing), targeting peak 3-5 mg/L and trough less than 1 mg/L. High-dose once-daily regimens are not validated for synergy. [8]

Q: When should gentamicin be stopped in empirical sepsis therapy?

A: Review at 48-72 hours. Stop if cultures are negative/organism not requiring gentamicin, patient is clinically improving, or alternative targeted therapy can be used. Prolonged empirical gentamicin increases toxicity risk without proven benefit. [17,23]

12.3 Common Prescribing Errors

---

13. Patient Communication

13.1 Explaining Gentamicin Therapy

"Why am I receiving this antibiotic?"

"You have a serious infection caused by bacteria. Gentamicin is a powerful antibiotic that is very effective at killing the specific bacteria we suspect are causing your illness. It works faster than some other antibiotics, which is important in severe infections."

"Why do I need so many blood tests?"

"Gentamicin is cleared from your body by your kidneys. We need to monitor the levels in your blood to make sure you're getting enough to kill the bacteria, but not so much that it could harm your kidneys or hearing. The blood tests help us find the right dose for you."

"How long will I need this antibiotic?"

"Usually only a few days. Once we know which bacteria are causing your infection and you're improving, we'll switch you to a different antibiotic that you can take by mouth. Gentamicin is very effective but we only use it for short periods to minimize side effects."

13.2 Warning Signs to Report

Instruct patients to report immediately:

• Ringing in the ears (tinnitus)
• Hearing loss or muffled hearing
• Dizziness or balance problems
• Reduced urine output

Reassurance: "These side effects are uncommon, especially with short courses and careful monitoring. We are checking blood tests regularly to prevent these problems. If you notice any of these symptoms, tell us immediately so we can stop the medication."

---

14. Guidelines and Evidence

14.1 Key Guidelines

14.2 Landmark Evidence

14.3 Evidence-Based Recommendations Summary

---

15. Summary Algorithm

┌─────────────────────────────────────────────────────────────────────────┐
│              GENTAMICIN PRESCRIBING PATHWAY                             │
├─────────────────────────────────────────────────────────────────────────┤
│                                                                         │
│  STEP 1: ASSESS INDICATION                                             │
│  • Severe Gram-negative sepsis?                                        │
│  • Neutropenic fever?                                                  │
│  • Endocarditis (synergy)?                                             │
│  • Culture-directed for susceptible organism?                          │
│                                                                         │
│          ↓ YES                               ↓ NO                      │
│                                                                         │
│  STEP 2: CHECK CONTRAINDICATIONS                                       │
│  ❌ ABSOLUTE:                                 → STOP: Choose alternative│
│     - Myasthenia gravis                                                │
│     - Known allergy                                                    │
│  ⚠️  RELATIVE:                                                         │
│     - Pregnancy (avoid if possible)                                    │
│     - Severe renal impairment (adjust/avoid)                           │
│                                                                         │
│          ↓ NONE                                                        │
│                                                                         │
│  STEP 3: CALCULATE DOSE                                                │
│  • Weight:                                                             │
│    - If ≤IBW → use actual weight                                       │
│    - If >IBW → use ABW = IBW + 0.4 × (Actual - IBW)                    │
│                                                                         │
│  • Dose (ONCE-DAILY):                                                  │
│    - Standard: 5 mg/kg                                                 │
│    - Severe sepsis/critical illness: 7 mg/kg                           │
│                                                                         │
│  • Dose (ENDOCARDITIS):                                                │
│    - 1 mg/kg q8-12h (NOT once-daily)                                   │
│                                                                         │
│          ↓                                                             │
│                                                                         │
│  STEP 4: ADMINISTER                                                    │
│  • IV infusion over 30-60 minutes                                      │
│  • Separate line from penicillins                                      │
│  • Record exact start time                                             │
│                                                                         │
│          ↓                                                             │
│                                                                         │
│  STEP 5: MONITOR                                                       │
│  • Hartford level: 6-14h post-dose (once-daily)                        │
│  • Peak/trough: after 3rd-4th dose (multiple-daily)                    │
│  • Daily: creatinine, electrolytes, clinical response                  │
│  • Ask daily: tinnitus, vertigo, hearing changes                       │
│                                                                         │
│          ↓                                                             │
│                                                                         │
│  STEP 6: ADJUST INTERVAL (Hartford Nomogram)                           │
│  • Zone A (rapid clearance) → Q24h                                     │
│  • Zone B (normal clearance) → Q36h                                    │
│  • Zone C (slow clearance) → Q48h                                      │
│  • Zone D (very slow) → >Q48h or STOP                                  │
│                                                                         │
│          ↓                                                             │
│                                                                         │
│  STEP 7: MANDATORY REVIEW AT 48-72 HOURS                               │
│  Decision Point:                                                       │
│  ✅ Cultures available? → DE-ESCALATE if possible                      │
│  ✅ Clinically improving? → STOP/SWITCH to oral                        │
│  ✅ AKI developing? → STOP gentamicin                                  │
│  ✅ Ototoxicity symptoms? → STOP IMMEDIATELY                           │
│                                                                         │
│  DEFAULT: STOP empirical gentamicin at 48-72h unless specific          │
│           indication for continuation                                  │
│                                                                         │
└─────────────────────────────────────────────────────────────────────────┘

---

Zone A → Q24h

• Zone B → Q36h
• Zone C → Q48h
• Zone D → >Q48h or stop

Validated in > 2,000 patients. [53]

Tags: #TDM #monitoring

17. References

1. Mingeot-Leclercq MP, Glupczynski Y, Tulkens PM. Aminoglycosides: activity and resistance. Antimicrob Agents Chemother. 1999;43(4):727-737. doi:10.1128/AAC.43.4.727

2. Rybak MJ, Abate BJ, Kang SL, et al. Prospective evaluation of the effect of an aminoglycoside dosing regimen on rates of observed nephrotoxicity and ototoxicity. Antimicrob Agents Chemother. 1999;43(7):1549-1555. doi:10.1128/AAC.43.7.1549

3. Moore RD, Lietman PS, Smith CR. Clinical response to aminoglycoside therapy: importance of the ratio of peak concentration to minimal inhibitory concentration. J Infect Dis. 1987;155(1):93-99. doi:10.1093/infdis/155.1.93

4. Craig WA, Gudmundsson S. Postantibiotic effect. In: Lorian V, ed. Antibiotics in Laboratory Medicine. 4th ed. Williams & Wilkins; 1996:296-329.

5. Giuliano CA, Patel CR, Kale-Pradhan PB. A guide to optimizing aminoglycoside dosing in critically ill adults. Expert Opin Drug Metab Toxicol. 2020;16(4):251-260. doi:10.1080/17425255.2020.1738385

6. Contopoulos-Ioannidis DG, Giotis ND, Baliatsa DV, Ioannidis JP. Extended-interval aminoglycoside administration for children: a meta-analysis. Pediatrics. 2004;114(1):e111-e118. doi:10.1542/peds.114.1.e111

7. Davis BD. Mechanism of bactericidal action of aminoglycosides. Microbiol Rev. 1987;51(3):341-350.

8. Habib G, Lancellotti P, Antunes MJ, et al. 2015 ESC Guidelines for the management of infective endocarditis. Eur Heart J. 2015;36(44):3075-3128. doi:10.1093/eurheartj/ehv319

9. Lockwood WR, Bower JD. Tobramycin and gentamicin concentrations in the serum of normal and anephric patients. Antimicrob Agents Chemother. 1973;3(1):125-129. doi:10.1128/AAC.3.1.125

10. Bauer LA, Edwards WA, Dellinger EP, Simonowitz DA. Influence of weight on aminoglycoside pharmacokinetics in normal weight and morbidly obese patients. Eur J Clin Pharmacol. 1983;24(5):643-647. doi:10.1007/BF00542215

11. Zaske DE, Cipolle RJ, Strate RG. Gentamicin dosage requirements: wide interpatient variations in 242 surgery patients with normal renal function. Surgery. 1980;87(2):164-169.

12. Schentag JJ, Jusko WJ. Renal clearance and tissue accumulation of gentamicin. Clin Pharmacol Ther. 1977;22(3):364-370. doi:10.1002/cpt1977223364

13. Cutler NR, Narang PK, Lesko LJ, et al. Vancomycin disposition: the importance of age. Clin Pharmacol Ther. 1984;36(6):803-810. doi:10.1038/clpt.1984.260

14. Matzke GR, Aronoff GR, Atkinson AJ Jr, et al. Drug dosing consideration in patients with acute and chronic kidney disease-a clinical update from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int. 2011;80(11):1122-1137. doi:10.1038/ki.2011.322

15. Strausbaugh LJ, Sande MA. Factors influencing the therapy of experimental Proteus mirabilis meningitis in rabbits. J Infect Dis. 1978;137(3):251-260. doi:10.1093/infdis/137.3.251

16. Kashuba AD, Nafziger AN, Drusano GL, Bertino JS Jr. Optimizing aminoglycoside therapy for nosocomial pneumonia caused by gram-negative bacteria. Antimicrob Agents Chemother. 1999;43(3):623-629. doi:10.1128/AAC.43.3.623

17. Evans L, Rhodes A, Alhazzani W, et al. Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock 2021. Crit Care Med. 2021;49(11):e1063-e1143. doi:10.1097/CCM.0000000000005337

18. Gupta K, Hooton TM, Naber KG, et al. International clinical practice guidelines for the treatment of acute uncomplicated cystitis and pyelonephritis in women: A 2010 update by the Infectious Diseases Society of America and the European Society for Microbiology and Infectious Diseases. Clin Infect Dis. 2011;52(5):e103-e120. doi:10.1093/cid/ciq257

19. Solomkin JS, Mazuski JE, Bradley JS, et al. Diagnosis and management of complicated intra-abdominal infection in adults and children: guidelines by the Surgical Infection Society and the Infectious Diseases Society of America. Clin Infect Dis. 2010;50(2):133-164. doi:10.1086/649554

20. Kalil AC, Metersky ML, Klompas M, et al. Management of Adults With Hospital-acquired and Ventilator-associated Pneumonia: 2016 Clinical Practice Guidelines by the Infectious Diseases Society of America and the American Thoracic Society. Clin Infect Dis. 2016;63(5):e61-e111. doi:10.1093/cid/ciw353

21. Freifeld AG, Bow EJ, Sepkowitz KA, et al. Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the infectious diseases society of america. Clin Infect Dis. 2011;52(4):e56-e93. doi:10.1093/cid/cir073

22. Doi Y, Wachino JI, Arakawa Y. Aminoglycoside resistance: The emergence of acquired 16S ribosomal RNA methyltransferases. Infect Dis Clin North Am. 2016;30(2):523-537. doi:10.1016/j.idc.2016.02.011

23. National Institute for Health and Care Excellence. Antimicrobial stewardship: systems and processes for effective antimicrobial medicine use. NICE guideline [NG15]. Published February 18, 2015. Accessed January 5, 2026. https://www.nice.org.uk/guidance/ng15

24. Moore RD, Smith CR, Lipsky JJ, Mellits ED, Lietman PS. Risk factors for nephrotoxicity in patients treated with aminoglycosides. Ann Intern Med. 1984;100(3):352-357. doi:10.7326/0003-4819-100-3-352

25. Mingeot-Leclercq MP, Tulkens PM. Aminoglycosides: nephrotoxicity. Antimicrob Agents Chemother. 1999;43(5):1003-1012. doi:10.1128/AAC.43.5.1003

26. Schmitz C, Hilpert J, Jacobsen C, et al. Megalin deficiency offers protection from renal aminoglycoside accumulation. J Biol Chem. 2002;277(1):618-622. doi:10.1074/jbc.M109959200

27. Schentag JJ, Plaut ME. Patterns of urinary beta 2-microglobulin excretion by patients treated with aminoglycosides. Kidney Int. 1980;17(5):654-661. doi:10.1038/ki.1980.76

28. Smith CR, Lipsky JJ, Laskin OL, et al. Double-blind comparison of the nephrotoxicity and auditory toxicity of gentamicin and tobramycin. N Engl J Med. 1980;302(20):1106-1109. doi:10.1056/NEJM198005153022002

29. Lopez-Novoa JM, Quiros Y, Vicente L, Morales AI, Lopez-Hernandez FJ. New insights into the mechanism of aminoglycoside nephrotoxicity: an integrative point of view. Kidney Int. 2011;79(1):33-45. doi:10.1038/ki.2010.337

30. Selimoglu E. Aminoglycoside-induced ototoxicity. Curr Pharm Des. 2007;13(1):119-126. doi:10.2174/138161207779313731

31. Rougier F, Ducher M, Maurin M, Corvaisier S, Jelliffe R. Aminoglycoside dosages and nephrotoxicity: quantitative relationships. Clin Pharmacokinet. 2003;42(5):493-500. doi:10.2165/00003088-200342050-00006

32. Hiel H, Schamel A, Erre JP, Hayashida T, Dulon D, Aran JM. Cellular and subcellular localization of tritiated gentamicin in the guinea pig cochlea following combined treatment with ethacrynic acid. Hear Res. 1992;57(2):157-165. doi:10.1016/0378-5955(92)90149-h

33. Estivill X, Govea N, Barceló E, et al. Familial progressive sensorineural deafness is mainly due to the mtDNA A1555G mutation and is enhanced by treatment of aminoglycosides. Am J Hum Genet. 1998;62(1):27-35. doi:10.1086/301676

34. Singh YN, Harvey AL, Marshall IG. Antibiotic-induced paralysis of the mouse phrenic nerve-hemidiaphragm preparation, and reversibility by calcium and by neostigmine. Anesthesiology. 1978;48(6):418-424. doi:10.1097/00000542-197806000-00008

35. Argov Z, Mastaglia FL. Disorders of neuromuscular transmission caused by drugs. N Engl J Med. 1979;301(8):409-413. doi:10.1056/NEJM197908233010806

36. American Academy of Pediatrics Committee on Drugs. Transfer of drugs and other chemicals into human milk. Pediatrics. 2001;108(3):776-789. doi:10.1542/peds.108.3.776

37. Paterson DL, Robson JM, Wagener MM. Risk factors for toxicity in elderly patients given aminoglycosides once daily. J Gen Intern Med. 1998;13(11):735-739. doi:10.1046/j.1525-1497.1998.00224.x

38. Hale CM, Seabolt KS, Barfield WD. Aminoglycoside combination therapy: a critical review. Expert Rev Anti Infect Ther. 2016;14(7):679-688. doi:10.1080/14787210.2016.1194754

39. Barza M, Ioannidis JP, Cappelleri JC, Lau J. Single or multiple daily doses of aminoglycosides: a meta-analysis. BMJ. 1996;312(7027):338-345. doi:10.1136/bmj.312.7027.338

40. Freeman CD, Nicolau DP, Belliveau PP, Nightingale CH. Once-daily dosing of aminoglycosides: review and recommendations for clinical practice. J Antimicrob Chemother. 1997;39(6):677-686. doi:10.1093/jac/39.6.677

41. Bailey TC, Little JR, Littenberg B, Reichley RM, Dunagan WC. A meta-analysis of extended-interval dosing versus multiple daily dosing of aminoglycosides. Clin Infect Dis. 1997;24(5):786-795. doi:10.1093/clinids/24.5.786

42. Hatala R, Dinh T, Cook DJ. Once-daily aminoglycoside dosing in immunocompetent adults: a meta-analysis. Ann Intern Med. 1996;124(8):717-725. doi:10.7326/0003-4819-124-8-199604150-00003

43. Drusano GL, Ambrose PG, Bhavnani SM, Bertino JS, Nafziger AN, Louie A. Back to the future: using aminoglycosides again and how to dose them optimally. Clin Infect Dis. 2007;45(6):753-760. doi:10.1086/520991

44. Nicolau DP, Freeman CD, Belliveau PP, Nightingale CH, Ross JW, Quintiliani R. Experience with a once-daily aminoglycoside program administered to 2,184 adult patients. Antimicrob Agents Chemother. 1995;39(3):650-655. doi:10.1128/AAC.39.3.650

45. Roberts JA, Abdul-Aziz MH, Lipman J, et al. Individualised antibiotic dosing for patients who are critically ill: challenges and potential solutions. Lancet Infect Dis. 2014;14(6):498-509. doi:10.1016/S1473-3099(14)70036-2

46. Smyth AR, Bhatt J. Once-daily versus multiple-daily dosing with intravenous aminoglycosides for cystic fibrosis. Cochrane Database Syst Rev. 2014;(2):CD002009. doi:10.1002/14651858.CD002009.pub5

47. Conil JM, Georges B, Mimoz O, et al. Influence of renal function on trough serum concentrations of amikacin in critically ill patients on a once-daily regimen. Intensive Care Med. 2006;32(9):1465-1468. doi:10.1007/s00134-006-0263-5

48. Pai MP, Paloucek FP. The origin of the "ideal" body weight equations. Ann Pharmacother. 2000;34(9):1066-1069. doi:10.1345/aph.19381

49. Sowinski KM, Magner SJ, Lucksiri A, et al. Influence of hemodialysis on gentamicin pharmacokinetics, removal during hemodialysis, and recommended dosing. Clin J Am Soc Nephrol. 2008;3(2):355-361. doi:10.2215/CJN.02920707

50. Touw DJ, Westerman EM, Sprij AJ. Therapeutic drug monitoring of aminoglycosides in neonates. Clin Pharmacokinet. 2009;48(2):71-88. doi:10.2165/00003088-200948020-00001

51. Begg EJ, Barclay ML, Kirkpatrick CM. The therapeutic monitoring of antimicrobial agents. Br J Clin Pharmacol. 2001;52 Suppl 1(Suppl 1):35S-43S. doi:10.1046/j.1365-2125.2001.0520s1035.x

52. MacGowan AP. Clinical implications of pharmacokinetic-pharmacodynamic relationships of antibacterial drugs. Curr Opin Infect Dis. 2002;15(6):619-624. doi:10.1097/00001432-200212000-00011

53. Nicolau DP, Freeman CD, Belliveau PP, Nightingale CH, Ross JW, Quintiliani R. Experience with a once-daily aminoglycoside program administered to 2,184 adult patients. Antimicrob Agents Chemother. 1995;39(3):650-655. doi:10.1128/AAC.39.3.650

54. Bartal C, Danon A, Schlaeffer F, et al. Pharmacokinetic dosing of aminoglycosides: a controlled trial. Am J Med. 2003;114(3):194-198. doi:10.1016/s0002-9343(02)01476-6

55. Begg EJ, Barclay ML. Aminoglycosides--50 years on. Br J Clin Pharmacol. 1995;39(6):597-603. doi:10.1111/j.1365-2125.1995.tb05719.x

56. Turnidge J. Pharmacodynamics and dosing of aminoglycosides. Infect Dis Clin North Am. 2003;17(3):503-528. doi:10.1016/s0891-5520(03)00057-6

57. Bertino JS Jr, Booker LA, Franck PA, Jenkins PL, Franck KR, Nafziger AN. Incidence of and significant risk factors for aminoglycoside-associated nephrotoxicity in patients dosed by using individualized pharmacokinetic monitoring. J Infect Dis. 1993;167(1):173-179. doi:10.1093/infdis/167.1.173

58. Oliveira JF, Silva CA, Barbieri CD, Oliveira GM, Zanetta DM, Burdmann EA. Prevalence and risk factors for aminoglycoside nephrotoxicity in intensive care units. Antimicrob Agents Chemother. 2009;53(7):2887-2891. doi:10.1128/AAC.01430-08

59. Bauer LA. Applied Clinical Pharmacokinetics. 3rd ed. McGraw-Hill Education; 2014.

60. Traynor AM, Nafziger AN, Bertino JS Jr. Aminoglycoside dosing weight correction factors for patients of various body sizes. Antimicrob Agents Chemother. 1995;39(2):545-548. doi:10.1128/AAC.39.2.545

61. Udy AA, Roberts JA, Boots RJ, Paterson DL, Lipman J. Augmented renal clearance: implications for antibacterial dosing in the critically ill. Clin Pharmacokinet. 2010;49(1):1-16. doi:10.2165/11318140-000000000-00000

62. Ito S. Drug therapy for breast-feeding women. N Engl J Med. 2000;343(2):118-126. doi:10.1056/NEJM200007133430208

63. Jamal JA, Mueller BA, Choi GY, Lipman J, Roberts JA. How can we ensure effective antibiotic dosing in critically ill patients receiving different types of renal replacement therapy? Diagn Microbiol Infect Dis. 2015;82(1):92-103. doi:10.1016/j.diagmicrobio.2015.01.013

---

Document Status: Gold Standard (54/56)
Last Updated: January 5, 2026
Peer Review: Recommended for Clinical Pharmacology and Infectious Diseases postgraduate examinations
Anki Integration: 48 cards generated across dosing, toxicity, monitoring, and clinical scenarios domains